| 72.45 2.91 (4.18%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 89.67 |
1-year : | 104.74 |
| Resists | First : | 76.77 |
Second : | 89.67 |
| Pivot price | 72.77 |
|||
| Supports | First : | 70.52 |
Second : | 66.66 |
| MAs | MA(5) : | 72.86 |
MA(20) : | 72.76 |
| MA(100) : | 55.09 |
MA(250) : | 41.96 |
|
| MACD | MACD : | 1.5 |
Signal : | 2.2 |
| %K %D | K(14,3) : | 45.4 |
D(3) : | 52.1 |
| RSI | RSI(14): 54.8 |
|||
| 52-week | High : | 76.77 | Low : | 23.95 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IONS ] has closed above bottom band by 44.3%. Bollinger Bands are 38.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 72.82 - 73.26 | 73.26 - 73.69 |
| Low: | 67.55 - 68.05 | 68.05 - 68.52 |
| Close: | 71.65 - 72.42 | 72.42 - 73.15 |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Tue, 11 Nov 2025
Ionis Announces Proposed Convertible Offering To Refinance 2026 Convertible Notes - TradingView
Tue, 11 Nov 2025
Ionis (NASDAQ: IONS) plans $700M convertible notes to refinance 2026 debt - Stock Titan
Tue, 11 Nov 2025
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes - Yahoo Finance
Mon, 10 Nov 2025
HC Wainwright & Co. Maintains Ionis Pharmaceuticals (IONS) Buy Recommendation - Nasdaq
Mon, 10 Nov 2025
Ionis: Near-Term Launches With Blockbuster Potential Boosts Upside Despite Stock Rally - Seeking Alpha
Mon, 10 Nov 2025
Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 159 (M) |
| Shares Float | 158 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 108.6 (%) |
| Shares Short | 13,700 (K) |
| Shares Short P.Month | 11,970 (K) |
| EPS | -1.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.97 |
| Profit Margin | -28.5 % |
| Operating Margin | 30.9 % |
| Return on Assets (ttm) | -5.9 % |
| Return on Equity (ttm) | -60 % |
| Qtrly Rev. Growth | 100.6 % |
| Gross Profit (p.s.) | 0.31 |
| Sales Per Share | 5.92 |
| EBITDA (p.s.) | -1.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -231 (M) |
| Levered Free Cash Flow | -169 (M) |
| PE Ratio | -41.17 |
| PEG Ratio | 0 |
| Price to Book value | 18.24 |
| Price to Sales | 12.23 |
| Price to Cash Flow | -50.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|